

Do current therapeutic anti-A β antibodies for Alzheimer's disease engage the target?

Andrew D. Watt · Gabriela A. N. Crespi · Russell A. Down · David B. Ascher · Adam Gunn · Keyla A. Perez · Catriona A. McLean · Victor L. Villemagne · Michael W. Parker · Kevin J. Barnham · Luke A. Miles

Received: 12 March 2014 / Revised: 28 April 2014 / Accepted: 28 April 2014
© Springer-Verlag Berlin Heidelberg 2014

Abstract Reducing amyloid- β peptide (A β) burden at the pre-symptomatic stages of Alzheimer's disease (AD) is currently the advocated clinical strategy for treating this disease. The most developed method for targeting A β is the use of monoclonal antibodies including bapineuzumab, solanezumab and crenezumab. We have synthesized these antibodies and used surface plasmon resonance (SPR) and mass spectrometry to characterize and compare the ability of these antibodies to target A β in transgenic mouse tissue as well as human AD tissue. SPR analysis showed that the

antibodies were able to bind A β with high affinity. All of the antibodies were able to bind A β in mouse tissue. However, significant differences were observed in human brain tissue. While bapineuzumab was able to capture a variety of N-terminally truncated A β species, the A β detected using solanezumab was barely above detection limits while crenezumab did not detect any A β . None of the antibodies were able to detect any A β species in human blood. Immunoprecipitation experiments using plasma from AD subjects showed that both solanezumab and crenezumab have extensive cross reactivity with non-A β related proteins. Bapineuzumab demonstrated target engagement with brain A β , consistent with published clinical data. Solanezumab and crenezumab did not, most likely as a result of a lack of specificity due to cross reactivity with other proteins

K. J. Barnham and L. A. Miles contributed equally to this work.

Electronic supplementary material The online version of this article (doi:10.1007/s00401-014-1290-2) contains supplementary material, which is available to authorized users.

A. D. Watt · R. A. Down · A. Gunn · K. A. Perez · C. A. McLean · V. L. Villemagne · K. J. Barnham
Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Melbourne, VIC 3010, Australia

A. D. Watt · R. A. Down
Department of Pathology, The University of Melbourne, Parkville, Melbourne, VIC 3010, Australia

A. D. Watt · R. A. Down · A. Gunn · K. A. Perez · K. J. Barnham
Neuroproteomics Platform, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Melbourne, VIC 3010, Australia

G. A. N. Crespi · D. B. Ascher · M. W. Parker · L. A. Miles
ACRF Rational Drug Discovery Centre and Biota Structural Biology Laboratory, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3056, Australia

C. A. McLean
Department of Anatomical Pathology, The Alfred Hospital, Melbourne, VIC 3084, Australia

V. L. Villemagne
Department of Medicine, The University of Melbourne, Parkville, Melbourne, VIC 3010, Australia

V. L. Villemagne
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC 3084, Australia

M. W. Parker · L. A. Miles (✉)
Department of Biochemistry and Molecular Biology, The University of Melbourne, Parkville, Melbourne, VIC 3010, Australia
e-mail: lmiles@svi.edu.au

K. J. Barnham (✉)
Department of Pharmacology, The University of Melbourne, Parkville, Melbourne, VIC 3010, Australia
e-mail: kbarnham@unimelb.edu.au



containing epitope overlap. This lack of target engagement raises questions as to whether solanezumab and cren-
ezumab are suitable drug candidates for the preventative
clinical trials for AD.

Keywords Alzheimer's disease · β -Amyloid ·
Bapineuzumab · Crenezumab · Solanezumab · Mass
spectrometry

Introduction

If the β -amyloid (A β) hypothesis of Alzheimer's disease (AD) is correct [1, 2], then the aim of any therapeutic intervention should be to remove toxic A β peptides from the brain. In attempts to achieve this, billions of dollars have been spent on clinical trials of anti-A β therapies for treatment of mild to moderate sufferers of AD. Now, after unmitigated trial failures in symptomatic patients, the field is looking for a therapeutic window earlier in the disease process where A β -directed interventions aim to prevent downstream pathology thereby delaying or stopping the development of dementia before significant damage to the brain has occurred.

Anti-A β antibodies are the most developed potential therapeutics for AD. Bapineuzumab (Pfizer, Johnson & Johnson) derives specificity for A β by binding it in a conformationally dependent manner, recognizing the five extreme N-terminal residues of A β as a helix with the N-terminus buried in the antibody surface [3]. Bapineuzumab is the only antibody clinically reported to reduce brain amyloid burden as well as decreasing cerebrospinal fluid (CSF) levels of both total Tau (t-Tau) and phosphorylated-Tau (p-Tau) in mild to moderate AD patients [4, 5]. However, despite successful target engagement, a large-scale Phase 3 trial of bapineuzumab to treat mild to moderate AD was prematurely halted when high doses were found to promote vasogenic oedema and other amyloid-related imaging abnormalities [6].

Solanezumab (Eli Lilly) targets the central region of A β and is reported to selectively bind to soluble monomeric A β with little affinity for oligomeric/fibrillar forms [7, 8]. On examination of transgenic mice expressing A β solely within the central nervous system (CNS), it was hypothesized that solanezumab acts as an A β sink in the periphery rather than in the CNS [9, 10], disrupting the equilibrium between plasma and brain A β , thereby driving amyloid from the brain into blood. Large Phase 3 clinical trials showed no evidence that administration of solanezumab shifted brain amyloid burden or downstream biological markers of disease. Post hoc analysis indicated that treatment with solanezumab slowed cognitive decline in patients with mild, but

not moderate, forms of the disease. This significant post hoc finding coupled with solanezumab's safety profile led to the compound being recommended as the first therapeutic agent to be assessed in the anti-amyloid treatment in asymptomatic Alzheimer's disease (A4) prevention trial [11].

Crenezumab, like solanezumab, binds the linear central portion of A β . It has been reported that crenezumab binds preferentially to A β fibrils and oligomers over monomeric species, and reduces amyloid plaque burden in transgenic mice [12]. However, despite crenezumab's reported affinity for oligomeric A β , it is important to note that there are currently no techniques with the capacity to monitor the in vivo burden of these putatively toxic species. Crenezumab is built on an IgG4 backbone, unlike bapineuzumab and solanezumab (both are IgG1). The IgG4 backbone enables the drug to mildly stimulate microglia enough for A β uptake but not to evoke an inflammatory response compared to the same drug on an IgG1 backbone and can therefore be administered at higher doses [12]. Crenezumab is the antibody chosen for the Alzheimer's prevention initiative's prevention trial in asymptomatic early-onset AD kindred in Colombia [13].

To date, direct comparisons between these antibodies have been limited, particularly with regard to their respective A β binding profiles. Therefore, the aim of the current investigation was to provide further characterization of the A β binding profiles of bapineuzumab, crenezumab, and solanezumab using synthetic A β peptides and surface plasmon resonance (SPR) before analyzing their binding profiles in both transgenic mouse and AD-affected tissues alongside comparable commercially available antibodies (WO2 and 4G8) using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF MS).

Methods

Comprehensive methodological descriptions are provided in Supplementary Material. Therapeutic antibodies and their Fabs were expressed in FreeStyle™ 293-F cells (Invitrogen), purified to homogeneity and stored in PBS in 20 μ L aliquots until required. pcDNA 3.1 vector (Invitrogen) constructs encoding each antibody chain were derived from synthetic DNA (Genscript) corresponding to published amino acid sequences: [14, 15] Bapineuzumab (Patent US 20080292625 A1) [16]; solanezumab (Patent WO 2001062801 A2, CAS 955085-14-0, ChEMBL1743072) [17]; crenezumab (Patent EP 2574345 A1, CAS 1095207-05-8, ChEMBL1743004) [18]. Murine antibody WO2 was obtained from the WEHI Monoclonal Antibody Facility and murine 4G8 was purchased from Covance (SIG-39220).



A β binding activity of the recombinant antibodies was tested by surface plasmon resonance (SPR) in parallel on a ProteOn XPR36 system (Bio-Rad). The A β peptides screened included A β _{1–28}, A β _{1–40}, A β _{1–42}, the N-terminally truncated peptides A β _{3–42}, A β _{4–42}, and the truncated and modified pEA β _{3–42}, and pEA β _{11–42}. A β _{1–28}, A β _{1–40}, A β _{1–42} were purchased from the Keck laboratory, Yale. All other A β peptides were made in-house using published methods [19].

Cortical samples were collected from 15-month-old female APP_{SWE}tg mice (Tg2576) and homogenized, while mouse blood samples were collected from 9-month-old female APP_{SWE}tg mice (Tg2576). Samples were stored at –80 °C.

Human brain tissue collected at autopsy and characterized by the Australian Brain Bank Network (ABBN) and preparation of the cortical homogenates was in accordance with previously reported methodologies [20]. Blood samples were collected from AD patients enrolled in the Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship Study of Aging [21]. All procedures were conducted in accordance with the Florey Neurosciences Ethics Committee.

Mass spectrometric analysis was carried out using ProteinChip® PS10 Arrays (Bio-Rad; CAT #C55-30044) using previously published protocols [20, 22].

6His-tagged Fabs for each therapeutic antibody were coupled to magnetic Nickel beads (Sigma) for immunoprecipitation in AD plasma according to the manufacturer's instructions. Biomolecules pulled down by the antibodies were proteolytically digested and detected by liquid chromatography (LC)-MS/MS on a LTQ Orbitrap Elite (Thermo Scientific). Acquired MS/MS data were searched against all human proteins in UniProt using Mascot [23, 24].

Results

Crenezumab has strong sequence similarities with solanezumab

While crenezumab has an IgG4 backbone, solanezumab has an IgG1 backbone; however, the complementarity determining regions (CDRs) are identical in length, with no insertions or deletions (see Supplementary Table 1). Three CDRs are of identical sequence (L2, L3, and the hypervariable H3). Besides a few very conservative amino acid substitutions, there are merely five non-conservative amino acid differences in total between the CDRs of solanezumab and crenezumab. CDR 2 of the heavy chain in solanezumab can be glycosylated at N56 on the heavy chain that has the potential to sterically hinder A β affinity.

Antibodies bind synthetic A β species with high affinity

Bapineuzumab, crenezumab, and solanezumab preparations studied here were expressed in human embryonic kidney cells, which might be different to the methods used for production of the clinically tested recombinant humanized samples and their murine equivalents studied in animal models. The clinical antibodies reportedly have a single N-linked glycosylation site in their respective Fc portions that mediates Fc receptor binding rather than ligand affinity and specificity of the complementarity determining regions conserved in humanized and murine equivalent antibodies. There is a single glycosylation site in the Fv domain of solanezumab: N56 of the heavy chain CDR2 that can sterically modify affinity for A β , from a K_D of 4 pM for fully glycosylated antibody to a K_D of 0.8 pM for the N56S/N56T mutated (unglycosylated) antibody (patent WO/2003/016466). This demonstrates that solanezumab retains extremely high affinity for A β regardless of differential glycosylation at this site; which might arise from differential expression systems for antibody production. We have used one of the preferred mammalian expression systems prescribed in each antibody patent to minimize the possibility of differential glycosylation. We initially performed SPR experiments to ensure that these antibodies were able to bind a range of synthetic A β peptides in accordance with their reported epitopes [16–18]. Mean rate association constants (k_a) for bapineuzumab, solanezumab, and crenezumab with captured A β as determined by SPR were found to be 7, 0.8 and $6 \times 10^3 \text{ M}^{-1} \text{ s}^{-1}$, respectively (Fig. 1a). Dissociation curves were flat and derived dissociation constant (k_d) values were in the order of $1 \times 10^{-5} \text{ s}^{-1}$ or lower (Supplementary Table 2). Drifting baselines, most likely due to A β aggregation, hampered efforts to resolve accurate K_D values. However, we established that the antibodies bapineuzumab, solanezumab and crenezumab recognized synthetic A β _{1–40} with binding constants in the low nanomolar and sub-nanomolar ranges when A β is conjugated to the chip (Fig. 1a). With antibodies coupled to the SPR chip and A β peptides introduced as analytes, the flat dissociation phase response curves for solanezumab persisted, yielding unreliable k_d values down to 10^{-17} s^{-1} , and a mean k_d value in the order of 10^{-6} s^{-1} , i.e., beyond the limits of detection. Apparent k_d values increased for bapineuzumab and crenezumab which were reproducible and in the order of 10^{-4} s^{-1} and 10^{-3} s^{-1} , respectively. Apparent K_D values for soluble A β species binding to bapineuzumab and crenezumab are in the order of low nanomolar, whereas apparent K_D values for solanezumab binding are in the picomolar or better range (Supplementary Table 2). Bapineuzumab did not recognize A β pre-treated with NaOH/HFIP in PBS, but demonstrated strong binding as reported above in PBS plus 0.005 % (v/v) Tween-20. This






Fig. 1 Recognition of synthetic Aβ species using bapineuzumab, crenezumab, and solanezumab. **a** Representative SPR binding response curves on the same coordinate axis for antibody binding to Aβ₁₋₄₀ captured on a NLH sensor chip at the C-terminus in PBS, pH 7.4, with 0.005 % (v/v) Tween-20. The maximum concentrations of bapineuzumab (red), solanezumab (blue), and crenezumab (green) are 2.9, 7.0, and 2.8 μM, respectively, with a series of tenfold dilutions. Only the three highest concentrations of each antibody and the blank are shown for clarity. Thick lines represent data points and the thin lines are fits obtained with the bivalent analyte model in ProteOn Manager Software package. **b, c** Representative SELDI-TOF MS spectra of 50 pM synthetic Aβ₁₋₄₀ and Aβ₁₋₄₂ arising from analysis with bapineuzumab, crenezumab, and solanezumab




Fig. 2 Spectral profiles of transgenic APP_{SWE} mouse tissue. Representative SELDI-TOF MS spectra arising from the analysis of transgenic APP_{SWE} (tg2576) mouse **a** brain homogenate ($n = 3$) and **b** plasma ($n = 3$) with bapineuzumab, crenezumab, solanezumab, and WO2

may have been due to the inhibition of aggregation or conformational change induced by the detergent. In either case, it highlights the pleomorphic nature of Aβ peptides and how care must be taken when interpreting affinity coefficients for these interactions.

With the antibodies conjugated to the sensor chip and Aβ peptides introduced as analytes, k_d for the solanezumab and crenezumab was similar for all peptides tested, namely, Aβ₁₋₂₈, Aβ₁₋₄₀, Aβ₁₋₄₂, Aβ₃₋₄₂, Aβ₄₋₄₂, pEAβ₃₋₄₂, and pEAβ₁₁₋₄₂ which all contain the shared linear epitope. Bapineuzumab showed no change in k_d for Aβ₁₋₂₈, Aβ₁₋₄₀, Aβ₁₋₄₂, but no binding was detected between the antibody and any Aβ species with an altered N-terminus (Supplementary Table 2). Bapineuzumab, solanezumab, and crenezumab when conjugated directly to the SELDI chip matrix readily

detected synthetic Aβ₁₋₄₀ and Aβ₁₋₄₂ at 50 pM by SELDI-TOF MS (Fig. 1b, c).

Antibodies bind Aβ in APP_{SWE} transgenic mice

The therapeutic antibodies were coupled to a SELDI-TOF array before the addition and incubation of either cortical homogenate ($n = 3$) or plasma ($n = 3$) from APP_{SWE} transgenic mice was added. Mass spectrometric analysis of these fractions showed that in APP_{SWE} transgenic mice cortical samples bapineuzumab, solanezumab, WO2 and 4G8 all capture a near identical range of C-terminally truncated Aβ species: Aβ₁₋₃₇, Aβ₁₋₃₈, Aβ₁₋₃₉, Aβ₁₋₄₀, and Aβ₁₋₄₂ (Fig. 2a). Crenezumab only captured the dominant species Aβ₁₋₄₀ and Aβ₁₋₄₂ with lower peak intensities. With the exception of crenezumab, all the antibodies captured




Fig. 3 Spectra profiles of AD-affected human tissue Representative SELDI-TOF MS spectra arising from the analysis of AD-affected **a** brain homogenate ($n = 4$) and **b** the blood cellular fraction ($n = 4$) with bapineuzumab, crenezumab, solanezumab, WO2, and 4G8

$A\beta_{1-40}$ in plasma collected from APP_{SWE} transgenic mice (Fig. 2b).

Not all antibodies recognize A β in AD-affected human brain tissue

As with the samples collected from the transgenic animals, analysis of AD-affected cortical homogenate and plasma was conducted using SELDI-TOF MS. This experiment revealed significant differential activities between the antibodies when analyzing the AD-affected brain homogenates ($n = 4$; Fig. 3a). The resulting spectra indicated that bapineuzumab, WO2, and 4G8 captured a spectrum of N-terminally truncated A β peptides ranging from A β_{5-42} through A β_{1-42} , with very strong signal-to-noise. In contrast, detection of A β species in the AD cortical homogenate when




Fig. 4 Spectral profiles of the AD-affected plasma. Representative SELDI-TOF MS spectra of plasma from AD patients demonstrated that all antibodies failed to resolve peaks consistent with known APP/A β species

using solanezumab and crenezumab was significantly lower with signals either being barely detectable above the noise or not detectable at all.

Therapeutic antibodies do not recognize A β species in the blood cellular fraction

We have previously shown that the cellular fraction of blood is rich in A β -related biomarkers [22]. Here, analysis of the blood cellular fraction indicated that the monomeric and dimeric A β species observed using WO2 and 4G8 were not detected using bapineuzumab, crenezumab, and solanezumab ($n = 4$; Fig. 3b). A single peak around 8 kDa was captured using all three antibodies; however, this did not align with any reported fragments of APP or A β and was considered to be the result of non-specific interactions.

There is no detectable A β in plasma

SELDI-TOF MS was also used for identification of A β species in AD-affected plasma samples ($n = 4$; Fig. 4). Bapineuzumab, crenezumab, solanezumab, and the laboratory standards WO2 and 4G8 were all unable to capture detectable levels of any A β species from AD-affected plasma samples, consistent with our earlier findings [11] and the short half-life of soluble A β in vivo [25]. The antibodies were all however, capable of binding synthetic A β_{1-42} spiked into the AD-affected plasma at picomolar concentrations (Supplementary Fig. 1), indicating that the exchangeable pool of A β observed in the transgenic animal models is not reflected in sporadic AD.



Table 1 Proteins identified following immunoprecipitation of AD plasma with crenezumab, and solanezumab

Protein	Gene symbol	UniProt ID	A β _{16–23} sequence alignment
			16 KLVFFAED 23
Probable ATP-dependent DNA helicase	HFM1	A2PYH4	147 KLVNFAED 154
Contactin-associated protein-like 3B	CNT3B	Q96NU0	240 KLVFFLNS 244
2-oxoglutarate and iron-dependent oxygenase domain-containing protein	OGFD1	Q8N543	206 KLVFFEVS 210
Cysteine-rich protein 3	CRIP3	Q6Q6R5	12 QPVFFAEK 16
Solute carrier family 2, member 13	SLC2A13	Q96QE2	517 YLVFFAPG 521 ^a
Autophagy-related protein 9B	ATG9B	Q674R7	531 QLVFFAGA 535
Neurotrimin	NTM	Q9P121	279 KLIFFNVS 283 ^a
Kelch domain containing 2	KLHDC2	Q9Y2U9	156 KLIFFGGY 160 ^a
Interleukin-12 receptor beta-1	IL12RB1	P42701	547 WLIFFASL 551 ^a
Peroxisomal bifunctional enzyme	EHHADH	Q08426	272 QYAFFAER 275 ^a
Cardiomyopathy associated 3	XIRP2	A4UGR9	24 PESDFAED 27 ^a
Zinc finger protein 429	ZN429	Q86V71	81 CSHFAED 84

AQ4 ^a Mapped in Plasma Proteomics Database

303 Solanezumab and crenezumab bind non-A β related species
304 in plasma

305 Given the poor performance of the therapeutic antibodies in
306 capturing A β in blood, we used immunoprecipitation (IP)
307 in conjunction with LC-MS/MS to better characterize the
308 mAb binding profiles in human plasma. No A β peptides
309 were detected with any of the antibodies. However, bap-
310 ineuzumab was the only antibody to pull down a construct
311 from the C-terminal cytoplasmic tail of APP (Supplemen-
312 tary Table 3). Given the N-terminal and conformational
313 requirements of bapineuzumab for A β , this species was
314 likely the BACE-derived A β precursor C99. Using cren-
315 ezumab and solanezumab, the IPs pulled down and identi-
316 fied just over 200 proteins in AD-affected plasma not seen
317 by bapineuzumab or beads alone. Twelve of these exhibited
318 sequence identity with the linear epitope (KLVFFAED)
319 central to the putative A β epitopes recognized by cren-
320 ezumab and solanezumab (Table 1).

321 Discussion

322 One of the key driving forces for the amyloid cascade
323 hypothesis is that the accumulation of cortical A β precedes
324 the clinical onset of AD by upwards of 20 years [26, 27].
325 Clinical validation of this hypothesis requires that lower-
326 ing cortical A β burden should lead to cognitive improve-
327 ments or that the reduction of pre-clinical A β accumulation
328 should prevent or delay the onset of disease. However, to
329 date anti-A β therapies have failed in the clinical setting,
330 raising questions about the validity of the amyloid hypoth-
331 esis of AD and lending strength to the argument that thera-
332 peutic interventions in the mild to moderate stages of AD

are simply a case of too little, too late [28–30]. It could
be argued, however, that the amyloid hypothesis has not
yet been adequately tested, as the therapeutic compounds
thus far selected for clinical evaluation have suffered from
a number of fundamental flaws, including an inability to
cross the blood–brain barrier, toxic side effects, question-
able mechanisms of action [30], and now questions regard-
ing whether appropriate target engagement is occurring.

Given this history, the field has now determined that the
best time to target A β accumulation is prior to symptom
onset before significant and irreversible damage has been
done to the brain. For this strategy to work, the chosen
drug(s) must be capable of reducing the pool of A β that is
thought to drive the disease, i.e., brain-derived A β . Studies
in transgenic animals have shown that bapineuzumab, cren-
ezumab, and solanezumab engage the target in these mod-
els successfully reducing A β burden [8, 10, 12]. Consist-
ent with these data utilizing SELDI-TOF MS technology,
our analysis showed that all the antibodies could capture
A β from transgenic mouse brain tissue (Fig. 2a). When we
examined human AD brain tissue, bapineuzumab was able
to capture an array of A β species, but at the same time both
solanezumab and crenezumab were very poor at capturing
the A β species present in the brain tissue (Fig. 3a), indicat-
ing a different spectrum of activity for solanezumab and
crenezumab between mouse and human tissue. While these
results were surprising, they were in line with reported
clinical outcomes in that bapineuzumab can successfully
reduce A β burden as detected by positron emission tomog-
raphy imaging studies [5], while solanezumab does not
[31].

Based on mouse studies, it has been suggested that
solanezumab does not work directly on brain A β , but
instead works as a peripheral sink targeting peripheral A β

which in turn lowers CNS A β by mass action. Indeed when we examined plasma from tg2576 mice, solanezumab was able to detect A β _{1–40} in plasma (Fig. 2b). However, none of the therapeutic antibodies were able to detect A β in either the plasma or the cellular fraction from human AD subjects (Figs. 3b, 4). The first thing to note from these data is that A β profiles in the mouse blood are completely different to those of human blood, once again highlighting that caution must be exercised when extrapolating results from transgenic animals into humans. Furthermore, it raises the question; why did these antibodies fail to capture any A β species? Our SPR data confirmed that all the antibodies have a high affinity for A β (Fig. 1) and the ability to capture A β species in complex biological milieu was confirmed by our examination of the mouse tissue (Fig. 2). So if affinity is not the issue, perhaps it is a question of the antibodies' specificity for A β ?

All of the therapeutic antibodies were raised against linear epitopes within the A β sequence. It is likely that these epitopes are at least partially present in other proteins and that the resulting cross reactivity with these proteins diminishes the ability of the antibodies to target A β . Immunoprecipitation experiments from human plasma (Table 1) indicated that cross reactivity does indeed occur and is likely to explain the poor ability of solanezumab and crenezumab to capture A β species in human tissue. The similar cross reactivity profiles of solanezumab and crenezumab were consistent with their sequence similarities. One of the proteins pulled down by both solanezumab and crenezumab was the IL12 receptor; this is interesting as a recent publication showed that modulation of the IL12 signaling pathway resulted in cognitive improvements in a transgenic mouse model of AD [32]. It should be noted that a driving force for the selection of solanezumab as a drug candidate for the preventative trials was the post hoc analysis that showed a small, but significant improvement in cognition in the mild AD subjects in Phase 3 trials.

In summary, two of the leading drug candidates for preventative clinical trials are effectively the same antibody indicating a lack of diversity in therapeutic strategies. These antibodies poorly recognize A β in human tissue as a result of cross reactivity, which is a well-known problem for therapeutic antibodies raised against linear target sequences [33–35]. This lack of specificity and target engagement for A β does not bode well for the prospects of success of these drugs in the preventative trials that are ultimately likely to validate the amyloid cascade hypothesis for AD. Bapineuzumab while raised against a linear epitope of A β , requires a specific conformation for binding [3]; this gives the antibody a degree of specificity and as a result this drug has clinically demonstrated target engagement, but unfortunately toxicity issues prevent further evaluation of this drug. Over stimulation of microglia or removal of

A β embedded in the vascular architecture of the AD brain has been suggested to explain bapineuzumab toxicity. This would recommend the use of an Fc-modified form of bapineuzumab, AAB-003 recently developed by Pfizer. Ultimately, if the amyloid cascade hypothesis is to be validated in a pre-symptomatic cohort, the drug utilized must be clinically proven to safely reduce cortical A β burden.

Acknowledgments This work was funded by the National Health and Medical Research Council of Australia (NHMRC) and we thank the AIBL Flagship Study of Aging for the provision of blood samples. Funding was also received from the Victorian Government Operational Infrastructure Support Scheme to St Vincent's Institute. D.B.A was supported by a Victoria Fellowship from the Victorian Government and a Leslie (Les) J. Fleming Churchill Fellowship from The Winston Churchill Memorial Trust. M.W.P. is an NHMRC Research Fellow.

References

- Hardy J, Selkoe DJ (2002) The amyloid hypothesis of alzheimer's disease: progress and problems on the road to therapeutics. *Science* 297:353–356. doi:10.1126/science.1072994
- Masters CL, Cappai R, Barnham KJ, Villemagne VL (2006) Molecular mechanisms for alzheimer's disease: implications for neuroimaging and therapeutics. *J Neurochem* 97:1700–1725
- Miles LA, Crespi GAN, Doughty L, Parker MW (2013) Bapineuzumab captures the n-terminus of the alzheimer's disease amyloid-beta peptide in a helical conformation. *Sci Rep* 3. <http://www.nature.com/srep/2013/130218/srep01302/abs/srep01302.html#supplementary-information>
- Blennow K, Zetterberg H, Rinne JO et al (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate alzheimer disease. *Arch Neurol* 69:1002–1010. doi:10.1001/archneurol.2012.90
- Rinne JO, Brooks DJ, Rossor MN et al (2010) 11c-pib pet assessment of change in fibrillar amyloid- β load in patients with alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. *Lancet Neurol* 9:363–372. doi:10.1016/S1474-4422(10)70043-0
- Sperling R, Salloway S, Brooks DJ et al (2012) Amyloid-related imaging abnormalities in patients with alzheimer's disease treated with bapineuzumab: a retrospective analysis. *Lancet Neurol* 11:241–249. doi:10.1016/s1474-4422(12)70015-7
- Imbimbo BP, Ottonello S, Frisardi V et al (2012) Solanezumab for the treatment of mild-to-moderate alzheimer's disease. *Expert Rev Clin Immunol* 8:135–149. doi:10.1586/eci.11.93
- Seubert P, Barbour R, Khan K et al (2008) Antibody capture of soluble abeta does not reduce cortical abeta amyloidosis in the pdapp mouse. *Neurodegener Dis* 5:65–71. doi:10.1159/000112834
- Citron M (2010) Alzheimer's disease: strategies for disease modification. *Nat Rev Drug Discov* 9:387–398. doi:10.1038/nrd2896
- DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-a beta antibody alters cns and plasma a beta clearance and decreases brain a beta burden in a mouse model of alzheimer's disease. *Proc Natl Acad Sci USA* 98:8850–8855. doi:10.1073/pnas.151261398
- Mullard A (2012) Sting of alzheimer's failures offset by upcoming prevention trials. *Nat Rev Drug Discov* 11:657–660. doi:10.1038/nrd3842
- Adolfsson O, Pihlgren M, Toni N et al (2012) An effector-reduced anti- β -amyloid (a β) antibody with unique a β binding



- properties promotes neuroprotection and glial engulfment of $\alpha\beta$. *J Neurosci* 32:9677–9689. doi:[10.1523/jneurosci.4742-11.2012](https://doi.org/10.1523/jneurosci.4742-11.2012)
13. Reiman EM, Langbaum JB, Fleisher AS et al (2011) Alzheimer's prevention initiative: a plan to accelerate the evaluation of pre-symptomatic treatments. *J Alzheimers Dis* 26(Suppl 3):321–329. doi:[10.3233/jad-2011-0059](https://doi.org/10.3233/jad-2011-0059)
 14. World Health Organisation (2008) Proposed inn: List 100. WHO Drug Inform 22
 15. World Health Organisation (2011) Poposed inn: List 105. WHO Drug Inform 25
 16. Schroeter S, Games KD (2008) Prevention and treatment of cerebral amyloid angiopathy: Us 12/106,206. US Patent Application
 17. Bales KR, Demattos R, Holtzman DM, Paul SM, Tsurushita N, Vasquez M (2001) Humanized antibodies that sequester amyloid beta peptide. US Patent Application
 18. Pfeifer A, Pihlgren M, Muhs AW, Ryan, Nicolau C, Greferath R (2008) Humanized antibodies to amyloid beta. US Patent Application
 19. Kok WM, Scanlon DB, Karas JA et al (2009) Solid-phase synthesis of homodimeric peptides: Preparation of covalently-linked dimers of amyloid [small beta] peptide. *Chem Commun*. doi:[10.1039/B912784D](https://doi.org/10.1039/B912784D) (6228–6230)
 20. Watt AD, Perez KA, Rembach A et al (2013) Oligomers, fact or artefact? Sds-page induces dimerization of beta-amyloid in human brain samples. *Acta Neuropathol* 125:549–564. doi:[10.1007/s00401-013-1083-z](https://doi.org/10.1007/s00401-013-1083-z)
 21. Ellis KA, Bush AI, Darby D et al (2009) The australian imaging, biomarkers and lifestyle (aibl) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of alzheimer's disease. *Int Psychogeriatr* 21:672–687. doi:[10.1017/S1041610209009405](https://doi.org/10.1017/S1041610209009405)
 22. Villemagne VL, Perez KA, Pike KE et al (2010) Blood borne amyloid-beta dimer correlates with clinical markers of alzheimer's disease. *J Neurosci* 30:6315–6322
 23. Koenig T, Menze BH, Kirchner M et al (2008) Robust prediction of the mascot score for an improved quality assessment in mass spectrometric proteomics. *J Proteome Res* 7:3708–3717. doi:[10.1021/pr700859x](https://doi.org/10.1021/pr700859x)
 24. Perkins DN, Pappin DJC, Creasy DM, Cottrell JS (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. *Electrophoresis* 20:3551–3567. doi:[10.1002/\(SICI\)1522-2683\(19991201\)20:18<3551:AID-ELPS3551>3.0.CO;2-2](https://doi.org/10.1002/(SICI)1522-2683(19991201)20:18<3551:AID-ELPS3551>3.0.CO;2-2)
 25. Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Poduslo JF (2005) Pharmacokinetic analysis of the blood-brain barrier transport of 125i-amyloid β protein 40 in wild-type and alzheimer's disease transgenic mice (app, ps1) and its implications for amyloid plaque formation. *J Pharmacol Exp Ther* 313:1370–1378. doi:[10.1124/jpet.104.081901](https://doi.org/10.1124/jpet.104.081901)
 26. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. *Lancet* 368:387–403
 27. Villemagne VL, Burnham S, Bourgeat P et al (2013) Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic alzheimer's disease: a prospective cohort study. *Lancet Neurol* 12:357–367. doi:[10.1016/S1474-4422\(13\)70044-9](https://doi.org/10.1016/S1474-4422(13)70044-9)
 28. Selkoe DJ (2011) Resolving controversies on the path to alzheimer's therapeutics. *Nat Med* 17:1060–1065
 29. Sperling RA, Jack CR, Aisen PS (2011) Testing the right target and right drug at the right stage. *Sci Transl Med* 3:111–133. doi:[10.1126/scitranslmed.3002609](https://doi.org/10.1126/scitranslmed.3002609)
 30. Watt AD, Villemagne VL, Barnham KJ (2013) Metals, membranes, and amyloid-beta oligomers: key pieces in the alzheimer's disease puzzle? *J Alzheimers Dis* 33(Suppl 1):283–293. doi:[10.3233/jad-2012-129017](https://doi.org/10.3233/jad-2012-129017)
 31. Pontecorvo M, Joshi A, Lu Met al. (2013) Relationship between solanezumab treatment and amyloid burden in mild to moderate ad patients. In: 7th Human Amyloid Imaging (HAI)
 32. Vom Berg J, Prokop S, Miller KR et al (2012) Inhibition of il-12/il-23 signaling reduces alzheimer's disease-like pathology and cognitive decline. *Nat Med* 18:1812–1819. doi:[10.1038/nm.2965](https://doi.org/10.1038/nm.2965)
 33. Berglund L, Andrade J, Odeberg J, Uhlén M (2008) The epitope space of the human proteome. *Protein Sci* 17:606–613. doi:[10.1110/ps.073347208](https://doi.org/10.1110/ps.073347208)
 34. Bonnycastle LL, Mehroke JS, Rashed M, Gong X, Scott JK (1996) Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage. *J Mol Biol* 258:747–762. doi:[10.1006/jmbi.1996.0284](https://doi.org/10.1006/jmbi.1996.0284)
 35. James LC, Roversi P, Tawfik DS (2003) Antibody multispecificity mediated by conformational diversity. *Science* 299:1362–1367. doi:[10.1126/science.1079731](https://doi.org/10.1126/science.1079731)

